趋化因子受体CXCR3在乳腺癌中的表达及意义
摘要
目的研究趋化因子受体CXCR3在乳腺癌中的表达,分析其与浸润性乳腺癌相关临床病理指标之间的关系。
方法应用RT-PCR和实时荧光定量PCR(Real-Time PCR)检测18例浸润性乳腺癌组织及其癌旁正常组织中CXCR3 mRNA的表达；应用免疫组织化学方法检测CXCR3在80例浸润性乳腺癌、20例乳腺纤维腺瘤和15例正常乳腺组织中的表达。
结果(1)RT-PCR和实时荧光定量PCR结果显示乳腺癌组织中CXCR3 mRNA表达水平明显高于癌旁正常组织(P<0.05)。(2)免疫组化结果显示,CXCR3在乳腺癌组织中的表达明显高于其在乳腺纤维腺瘤和正常乳腺组织中的表达(P<0.05)；乳腺癌组织中淋巴结转移阳性组CXCR3的表达明显高于淋巴结转移阴性组(P<0.05)；CXCR3表达水平与乳腺癌患者淋巴结转移累及数目、肿瘤大小和pTNM分期呈显著正相关(P<0.05)。
结论趋化因子受体CXCR3是一类参与乳腺癌病程进展的重要分子,其表达与多项临床病理指标,尤其是淋巴结转移密切相关,提示其可作为预测乳腺癌淋巴结转移及预后的免疫病理学指标。
Objective To investigate the expression of CXCR3 and its association with clinicopathologic features in breast carcinoma.
Methods The expression levels of CXCR3 in eighteen samples of breast cancer and corresponding normal tissues were investigated using reverse transcriptase-polymerase chain reaction (RT-PCR) analysis, real-time RT-PCR analysis.Immunohistochemistry was carried out to examine the expression of CXCR3 in 80 breast cancers,20 breast fibroadenoma and 15 normal breast tisues.
Results (1) RT-PCR analysis showed higher levels of CXCR3 in breast cancer tissues than that in normal breast tissues. Real-time RT-PCR analysis showed that expression levels of CXCR3 in breast cancer tissues were significantly higher than that in the corresponding normal breast tissues(P<0.05). (2) Immunohistochemistry analysis showed that the positive rate of CXCR3 in breast cancer tissues was significantly higher than that in breast fibroadenoma and normal breast tisues(P<0.05). The expression levels of CXCR3 in lymph node-positive group was higher than that in lymph node—negative group(P<0.05); The expression of CXCR3 was positively correlated with the number of positive lymph node involved by metastasis, tumor size and pTNM tumor stage(P<0.05).
Conclusions Chemokine receptor CXCR3 was up-regulated in breast cancer, and was associated with the progression of breast cancer; CXCR3 might be a novel molecular marker to predict lymph node metastasis and prognosis of breast cancer.
方法应用RT-PCR和实时荧光定量PCR(Real-Time PCR)检测18例浸润性乳腺癌组织及其癌旁正常组织中CXCR3 mRNA的表达；应用免疫组织化学方法检测CXCR3在80例浸润性乳腺癌、20例乳腺纤维腺瘤和15例正常乳腺组织中的表达。
结果(1)RT-PCR和实时荧光定量PCR结果显示乳腺癌组织中CXCR3 mRNA表达水平明显高于癌旁正常组织(P<0.05)。(2)免疫组化结果显示,CXCR3在乳腺癌组织中的表达明显高于其在乳腺纤维腺瘤和正常乳腺组织中的表达(P<0.05)；乳腺癌组织中淋巴结转移阳性组CXCR3的表达明显高于淋巴结转移阴性组(P<0.05)；CXCR3表达水平与乳腺癌患者淋巴结转移累及数目、肿瘤大小和pTNM分期呈显著正相关(P<0.05)。
结论趋化因子受体CXCR3是一类参与乳腺癌病程进展的重要分子,其表达与多项临床病理指标,尤其是淋巴结转移密切相关,提示其可作为预测乳腺癌淋巴结转移及预后的免疫病理学指标。
Objective To investigate the expression of CXCR3 and its association with clinicopathologic features in breast carcinoma.
Methods The expression levels of CXCR3 in eighteen samples of breast cancer and corresponding normal tissues were investigated using reverse transcriptase-polymerase chain reaction (RT-PCR) analysis, real-time RT-PCR analysis.Immunohistochemistry was carried out to examine the expression of CXCR3 in 80 breast cancers,20 breast fibroadenoma and 15 normal breast tisues.
Results (1) RT-PCR analysis showed higher levels of CXCR3 in breast cancer tissues than that in normal breast tissues. Real-time RT-PCR analysis showed that expression levels of CXCR3 in breast cancer tissues were significantly higher than that in the corresponding normal breast tissues(P<0.05). (2) Immunohistochemistry analysis showed that the positive rate of CXCR3 in breast cancer tissues was significantly higher than that in breast fibroadenoma and normal breast tisues(P<0.05). The expression levels of CXCR3 in lymph node-positive group was higher than that in lymph node—negative group(P<0.05); The expression of CXCR3 was positively correlated with the number of positive lymph node involved by metastasis, tumor size and pTNM tumor stage(P<0.05).
Conclusions Chemokine receptor CXCR3 was up-regulated in breast cancer, and was associated with the progression of breast cancer; CXCR3 might be a novel molecular marker to predict lymph node metastasis and prognosis of breast cancer.
引文
[1]Muller A, Homey B, et al. Involvement of chemokine receptors in breast cancer metastasis [J].Nature,2001,410(6824):50-56.
[2]Tavassoli F A, Devilee P. World Health Organization classification of tumours. Pathologv and genetics of tumours of the breast and female genital organs.Lyon:IARC Press,2003.10.
[3]Klatte T, Seligson D B, John T, et al. The Chemokine Receptor CXCR3 is an Independent Prognostic Factor in Patients With Localized Clear Cell Renal Cell Carcinoma [J]. The Journal of Urology,2008,179:61-66.
[4]Liu Y L, Yu J M, Song X R, el al. Regulation of the chemokine receptor CXCR4 and metastasis by hypoxia-inducible factor in non small cell lung cancer cell lines [J]. Cancer Biol Ther,2006,5:1320-1326.
[5]Chinni S R, Sivalogan S, Dong z, el al. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells:the role of bone microenvironment—associated CXCL12 [J]. Prostate,2006,66:32-48.
[6]Suyama T, Furuya M, Nishiyama M, et al. Up-Regulation of the Interferon-γ (IFN-I)-Inducible Chemokines IFN-Inducible T-Cell a Chemoattractant and Monokine Induced by IFN-I and of their Receptor CXC Receptor 3 in Human Renal Cell Carcinoma [J]. Cancer,2005,103:258-267.
[7]陈瑜,张德新,郭长存,等.趋化因子受体CXCR3在胃癌中的表达[J].胃肠病学,2004,9(5)：266-69.
[8]Lilach G B, Eran N, Orit S A, et al. The expression of the chemokine receptor CXCR3 and its ligand CXCL10 in human breast adenocarcinoma cell lines [J]. Immunology Letters 2004,92:171-178.
[9]Datta D, Flaxenburg J A, Laxmanan S, et al. Ras-induced Modulation of CXCL10 and Its Receptor Splice Variant CXCR3-B in MDA-MB-435 and MCF-7 Cells:Relevance for the Development of Human Breast Cancer [J]. Cancer Res,2006,66(19):9509-9518.
[10]Walser T C, Rifat S, Ma X, et al.Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer [J]. Cancer Res,2006,66:7701-7707.
[11]Pradelli E, Babou K S, Michiels J F, et al. Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs [J]. Int. J. Cancer,2009,125:2586-2594.
[12]Maekawa S, Iwasaki A, et al. Association between the expression of chemokin receptors CCR7 and CXCR3, and lymph node metastatic potential in lung adenocarcinoma [J]. Oncology Reports,2008,19:1461-1468.
[13]Monteagudo C, Martin J M, Jorda E, et al. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma:correlation with clinicopathologic prognostic factors [J].J Clin Pathol,2007,60:596-599.
[14]Kawada K, Hosogi H, et al. Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes [J]. Oncogene,2007,26:4679-4688.
[15]Zipin R A, Meshel T, et al. CXCL10 promotes invasion-related properties in human colorectal carcinoma cells [J]. Cancer Res,2007,67:3396-405.
[16]Scotten C J, Wilson J L, Scott K, et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer [J]. Cancer Res,2002,62:5930-5938.
[17]Shi M, Guo R P, Zhang C Q, et al. Expression of CXCR3 in Hepatocellular Carcinoma [J]. Chinese Journal of Cancer,2006,25(10):1232-1237.
[18]Smith M, Luker K E, Gargow J R, et al. CXCR4 regulates.growth of both primary and metastatic breast cancer [J]. Cancer Res,2004,64:04-12.
[19]《乳腺癌Her2检测指南(2009版)》编写组.乳腺癌Her2检测指南(2009版).中华病理学杂志,2009,38(12)：836-840.
[20]姚晓英,宋晖.趋化性细胞因子与乳腺癌的转移[J].中国癌症杂志,2003,13(4)：381-384.
[21]Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4 [J]. Semin Cancer Biol,2004,4(3):171-179.
[22]Furuya M, Suyama T, Usui H, et al. Up-regulation of CXC mokines and their receptors:implications for proinflammatory microronments of ovarian carcinomas and endometriosis [J]. Hum Pathol 2007,38 (11):1676-87.
[23]Luster AD, Leder P. IP-10, a C-X-C chemokine, elicits a potent thymus dependent antitumor response in vivo [J]. J Exp Med,1993,178:1057-65.
[24]Goldberg-Bittman L, Sagi-Assif 0, Meshel T, et al. Cellular character-istics of neuroblastoma cells:regulation by the ELR-CXC chemokine CXCL10 and expression of a CXCR3-like receptor [J]. Cytokine 2005,29:105-17.
[25]Suyama T, Furuya M, Nishiyama M, et al. Up-regulation of the interferon gamma (IFN-gamma)-inducible chemokines IFN-inducible T-cell alpha chemoattractant and monokine induced by IFN-gamma and of their receptor CXC receptor 3 in human renal cell carcinoma [J]. Cancer,2005,103(2): 258-267.
[26]Robledo M M, Bartolome R A, Longo N, et al. Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells [J]. J Biol Chem,2001,276(48):45098-45105.
[27]Kawada K, Sonoshita M, Sakashita H, et al. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes [J]. Cancer Res,2004, 64 (11):4010-4017.
[1]Balkwill F, Mantovani A. Inflammation and cancer:back to Virchow? [J].Lancet,2001,357(9255):539-545.
[2]姚晓英,宋晖.趋化性细胞因子与乳腺癌的转移[J].中国癌症杂志,2003,13(4)：381-384.
[3]Richmond A, Thomas H G. Melanoma growth stimulatory activity:isolation from human melanoma tumors and characterization of tissue distribution[J]. Cell Biochem,36(1988):185-198.
[4]Addison C L, Daniel T O, et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+CXC chemokine-induced angiogenic activity [J]. Immunol,165 (2000):5269-5277.
[5]Dhawan P, Richmond A.Role of CXCL1 in tumorigenesis of melanoma [J]. J Leukoc Biol,2002,72(1):9-18.
[6]Luan J, Shattuck B H,et al. Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression [J].J Leukoc Biol,1997,62:588-597.
[7]Burger M, Burger J A, et al. Point mutation causing constitutive signaling of CXCR2 leads to transforming activity similar to Kaposi's sarcoma herpesvirus-G protein-coupled receptor [J]. Immunol,1999,163:2017-2022.
[8]Gershengorn M C, Geras R E, et al. Chemokines activate Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor in mammalian cells in culture [J].J Clin Invest,1998,102:1469-1472.
[9]Park J Y, Park K H, et al. CXCL5 overexpression is associated with late stage gastric cancer [J]. Cancer Res Clin Oncol,2007,133:835-840.
[10]Miyazaki H, Patel V, Wang-H. Down-regulation of CXCL5 inhibits squamous carcinogenesis [J]. Cancer Res,2006,66:4279-4284.
[11]Arenberg D A, Keane M P, DiGiovine B, et al. Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer [J]. J Clin Invest,1998,102:465-472.
[12]Proost P, Wuyts A, et al. Human and bovine granulocyte. chemotactic protein-2:complete amino acid sequence and functional characterization as chemokines[J]. Biochemistry,1993,32:10170-10177.
[13]Strieter R M, Polverini P J, et al.The functional role of the ELR motif in CXC chemokine-mediated angiogenesis[J]. J Biol Chem,1995,270:27348-27357.
[14]E. Van Coillie, I. Van Aelst, A. Wuyts, R. Vercauteren, R. Devos, C. De Wolf-Peeters, J. Van Damme, G. Opdenakker. Tumor angiogenesis induced by granulocyte chemotactic protein-2 as a countercurrent principle [J]. Am J Pathol,2001,159:1405-1414.
[15]A. Li, M.L. Varney, J. Valasek, M. Godfrey, B. J. Dave, R. K. Singh. Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis [J]. Angiogenesis,2005,8:63-71.
[16]H. Kamohara, M. Takahashi, T. Ishiko, M. Ogawa, H. Baba. Induction of interleukin-8 (CXCL-8) by tumor necrosis factor-alpha and leukemia inhibitory factor in pancreatic carcinoma cells:Impact of CXCL-8 as an autocrine growth factor [J]. Int J Oncol,2007,31:627-632.
[17]M. L. Varney, S. L. Johansson, R. K. Singh.Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma [J]. Am J Clin Pathol,2006,125:209-216.
[18]S. Molica, G. Vitelli, D. Levato, L. Levato, A. Dattilo, G.M. Gandolfo, Clinico-biological implications of increased serum levels of interleukin-8 in B-cell chronic lymphocytic leukemia [J]. Haematologica,1999,84:208-211.
[19]A. E. Proudfoot, T. M. Handel, Z. Johnson, E. K. Lau, P. LiWang, I. Clark-Lewis, F. Borlat, T. N. Wells, M.H.Kosco-Vilbois. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines [J]. Proc Natl Acad Sci USA,2003,100:1885-1890.
[20]De Larco JE, Wuertz BR, Rosner KA, et al. A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells [J].Am J Pathol,2001,158(2):639-646.
[21]Freund A,Chauveau C,Brouillet JP, et al. IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells[J].Oncogene,2003,22(2):256-265.
[22]A. Wuyts, N. Van Osselaer, A. Haelens, I. Samson, P. Herdewijn, A. Ben-Baruch, J.J. Oppenheim, P. Proost,J. Van Damme. Characterization of synthetic human granulocyte chemotactic protein 2:usage of chemokine receptors CXCR1 and CXCR2 and in vivo inflammatory properties [J]. Biochemistry,1997,36:2716-2723.
[23]M.N. Wente, M. P. Keane, M. D. Burdick, H. Friess, M. W.Buchler, G.0. Ceyhan, H. A. Reber, R. M. Strieter,O. J. Hines. Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis [J]. Cancer Lett,2006,241:221-227.
[24]Y.M. Zhu, S. J. Webster, D. Flower, P. J. Woll. Interleukin-8/CXCL8 is a growth factor for human lung cancer cells [J].Br J Cancer,2004,91:1970-1976.
[25]Zhuo Tang, M. D. Minghuan Yu, M. D. Ph. D. Fred Miller, Ph. D. Richard S. Berk, Ph. D. Gerard Tromp, Ph. D. Mary Ann Kosir, M. D. Increased invasion through basement membrane by CXCL7-transfected breast cells [J]. The American Journal of Surgery (2008) 196,690-696.
[26]Takahito Suyama, Mitsuko Furuya, Mariko Nishiyama, et al. Up-Regulation of the Interferon γ (IFN-I)-Inducible Chemokines IFN-Induciblea T-Cell Chemoattractant and Monokine Induced by IFN-I and of their Receptor CXC Receptor 3 in Human Renal Cell Carcinoma [J]. Cancer 2005;103:258-67.
[27]陈瑜,张德新,郭长存,等.趋化因子受体CXCR3在胃癌中的表达[J].胃肠病学,2004;9(5)：266-69.
[28]Lilach Goldberg-Bittman, Eran Neumark,Orit Sagi-Assif,et al. The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines [J]. Immunology Letters 2004;92:171-178.
[29]Dipak Datta,.Jesse A. Flaxenburg, Sreenivas Laxmanan, et.al. Ras-induced Modulation of CXCL10 and Its Receptor Splice Variant CXCR3-B in MDA-MB-435 and MCF-7 Cells:Relevance for the Development of Human Breast Cancer [J]. Cancer Res 2006; 66(19):9509-18.
[30]T. C. Walser, S. Rifat, X. Ma, N. Kundu, C. Ward,0. Goloubeva, M. G. Johnson, J. C. Medina, T. L. Collins, A.M. Fulton. Antagonism of CXCR3 inhibits lung metas-tasis in a murine model of metastatic breast cancer [J]. Cancer Res,2006,66:7701-7707.
[31]Emmanuelle Pradelli, Babou Karimdjee S, Jean F M, et al. Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs [J]. Int J Cancer,2009,125:2586-2594.
[32]Shinichi Maekawa,Akinori Iwasaki, Takayuki Shirakusa, et,al. Association between the expression of chemokin receptors CCR7 and CXCR3, and lymph node metastatic potential in lung adenocarcinoma [J]. Oncology Reports,2008,19:1461-1468.
[33]Monteagudo C, Martin JM, Jorda E, Llombart-Bosch A. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathologic prognostic factors[J]. J Clin Pathol,2007,60:596-9.
[34]Kawada K, Hosogi H, Sonoshita M, et al. Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes[J]. Oncogene,2007,26:4679-88.
[35]Zipin-Roitman A, Meshel T, Sagi-Assif 0, et al. CXCL10 promotes invasion-related properties in human colorectal carcinoma cells[J]. Cancer Res,2007,67:3396-405.
[36]Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis[J]. Nature,2001,410:50-56.
[37]Li F,Zhu HS, Han ZQ,et al. Effects of chemokine receptor and its ligand on migration of ovarian cancer cells [J]. cancer,2005,24(1):23-27.
[38]Lee BC,Lee TH, Avraham S, et al. Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1 alpha in breast cancer cell migration through human brain microvascular endothelial cells [J].Mol Cancer Res,2004,2(6):327-338.
[39]Schimanski CC, Schwald S, Simiantonaki N, et al.Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer [J]. Clin Cancer Res,2005,11(5):1743-1750.
[40]Eisenhardt A,Frey U,Tack M,et al.Expression analysis and potential functional role of the CXCR4 chemokine receptor in bladder cancer [J]. Eur Urol,2005,47(1):111-117.
[41]Mochizuki H, Matsubara A, Teishima J, et al. Interaction of Ligand receptor system between stromal-cell-derived factor-1 and CXC chemokine receptor 4 in human prostate cancer:a possible predictor of metastasis [J]. Biochem Biophys Res Commun,2004,320(3):656-663.
[42]Sato N, Matsubayashi H, Fukushima N, et al. The chemokine receptor CXCR4 is regulated by DNA methylation in pancreatic cancer [J]. Cancer Biol Ther,2005,4(1):70-76.
[43]Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4 [J]. Semin Cancer Biol,2004,4(3):171-179.
[1]魏永昆,朱虹光,周平,等.滑膜肉瘤32例临床病理分析.诊断病理学杂志,2002,9(2)：73-76.
[2]杨翎,范钦和,张炜明.滑膜肉瘤融合基因SYT2SSX的检测及意义分析.临床与实验病理学杂志,2004,20(5)：576-9.
[3]Tatsuya Hosono, Mitsugu Hironaka, Akira Kobayashi, et, al. Primary Pulmonary Synovial Sarcoma Confirmed by Molecular Detection of SYT-SSX1 Fusion Gene Transcripts:a Case Report and Review of the Literature. J Clin Oncol,2005,35(5)274-279.
[4]Smith TA, Machen SK, Fisher C, et, al. Usefulness of cytokeratin subsets for distinguishing monophasic synovial sarcoma from malignant peripheral nerve sheath tumor. Am J Clin Pathol,1999,112(5):641-8.
[5]Mai P. Hoang, Prasanna Sinkre, Jorge Albores-Saavedra, et, al. Expression of Protein Gene Product 9.5 in Epithelioid and Conventional Malignant Peripheral Nerve Sheath Tumors. Arch Pathol Lab Med,2001,125:1321-1325.
[6]Hiroshi Katol, Masahito Hatori, Shoichi Kokubun, et, al. CA125 Expression in Epithelioid Sarcoma. J Clin Oncol 2004,34(3)149-154.
[7]Mousa A. Al-Abbadi,; Nidal M. Almasri, Samer Al-Quran, et, al. Cytokeratin and Epithelial Membrane Antigen Expression in Angiosarcomas. Arch Pathol Lab Med,2007,131:288-292.
[8]Kimberly H Allison, Brian J. Yoder, Mary P. Bronner, et, al. Angiosarcoma Involving the Gastrointestinal Trac A Series of Primary and Metastatic Cases. Am J Surg Pathol,2004,28:298-307.
[9]Boudovd L, Michal M, Kinkor Z, et, al. sclerosing epitheral f ibrosarcoma. Cesk Patol,2001,37(4):158-62.
[10]Jun Lwata, Christopher D. M. Fletcher. immunohistochemical detection of CK and EMA in leiomyosarcoma, pathology international,2000, 50:7-14
[11]Kokada, T Hasegawa, R Yokoyama, et, al. Osteosarcoma with cytokeratin expression:a clinicopathological study of six cases with an emphasis on differential diagnosis from metastatic cancer. J Clin Pathol,2003, 56:742-746.
[12]Okada K, Hasegawa T, Yokoyama R. Rossete-forming epithelioid osteosarcoma:a histologic subtype with highly aggressive clinical behavior. Hum Pathol,2001 Jul,32(7):726-33.
[13]Louis Guillou, Jean Benhattar, Carole Gengler, et, al. Translocation positive Low-grade Fibromyxoid Sarcoma:Clinicopathologic and Molecular Analysis of a Series Expanding the Morphologic Spectrum and Suggesting Potential Relationship to Sclerosing Epithelioid Fibrosarcoma. Am J Surg Pathol 2007,31:1387-1402.
[14]王坚,朱雄增.纤维肉瘤少见亚型的诊断及鉴别诊断.Chin J Pathol,32(5)：469-74.
[15]Collini, Pabla, Sampietro, Giuseppe, Bertulli, Rossella. Cytokeratin Immunoreactivity in 41 Cases of ES/PNET Confirmed by Molecular Diagnostic Studies. Am J Surg Pathol 2001,25(2):273-4.
[16]W Glenn McCluggage, Vaiyapuri P Sumathi, Marisa R Nucci, et, al. Ewing family of tumours involving the vulva and vagina:report of a series of four cases. J Clin Pathol,2007,60:674-680.
[17]Srivastava A, Rosenberg AE, Selig M, et, al. Keratin-positive Ewing's sarcoma:an ultrastructural study of 12 cases. Int J Surg Pathol,2005, 13(1):43-50.
[18]Andrew L. Folpe, MD, John R. Goldblum, MD, Brian P. Rubin, MD, et, al. Morphologic and Immunophenotypic Diversity in Ewing Family Tumors. Am J Surg Pathol 2005,29:1025-1033.
[19]魏清柱,刘艳辉,庄恒国,等.RT-PCR法检测EWS-FLI融合基因诊断尤文肉瘤与外周原始神经外胚层瘤.J Diag Pathol, February 2007,14(1):32-35。
[20]Sandra Gebhard, M.D., Jean-Michel Coindre, M. D, et, al. Pleomorphic Liposarcoma:Clinicopathologic, Immunohistochemical and Follow-up Analysis of 63 Cases. Am J Surg Pathol,25(6):601-616.
[21]Masanori Hisaoka, Tsuyoshi Ishida, Tseng-Tong Kuo, et, al. Clear Cell Sarcoma of Soft Tissue A Clinicopathologic, Immunohistochemical and Molecular Analysis of 33 Cases. Am J Surg Pathol,2008,32:452-460.
[22]Mi-Woo Lee, Kowan-Ja Jee, Jae-Yoon Ro, et, al. Proximal-type epithelioid sarcoma:case report and result of comparative genomic hybridization. J Cutan Pathol,2004,31:67-71.
[2]Tavassoli F A, Devilee P. World Health Organization classification of tumours. Pathologv and genetics of tumours of the breast and female genital organs.Lyon:IARC Press,2003.10.
[3]Klatte T, Seligson D B, John T, et al. The Chemokine Receptor CXCR3 is an Independent Prognostic Factor in Patients With Localized Clear Cell Renal Cell Carcinoma [J]. The Journal of Urology,2008,179:61-66.
[4]Liu Y L, Yu J M, Song X R, el al. Regulation of the chemokine receptor CXCR4 and metastasis by hypoxia-inducible factor in non small cell lung cancer cell lines [J]. Cancer Biol Ther,2006,5:1320-1326.
[5]Chinni S R, Sivalogan S, Dong z, el al. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells:the role of bone microenvironment—associated CXCL12 [J]. Prostate,2006,66:32-48.
[6]Suyama T, Furuya M, Nishiyama M, et al. Up-Regulation of the Interferon-γ (IFN-I)-Inducible Chemokines IFN-Inducible T-Cell a Chemoattractant and Monokine Induced by IFN-I and of their Receptor CXC Receptor 3 in Human Renal Cell Carcinoma [J]. Cancer,2005,103:258-267.
[7]陈瑜,张德新,郭长存,等.趋化因子受体CXCR3在胃癌中的表达[J].胃肠病学,2004,9(5)：266-69.
[8]Lilach G B, Eran N, Orit S A, et al. The expression of the chemokine receptor CXCR3 and its ligand CXCL10 in human breast adenocarcinoma cell lines [J]. Immunology Letters 2004,92:171-178.
[9]Datta D, Flaxenburg J A, Laxmanan S, et al. Ras-induced Modulation of CXCL10 and Its Receptor Splice Variant CXCR3-B in MDA-MB-435 and MCF-7 Cells:Relevance for the Development of Human Breast Cancer [J]. Cancer Res,2006,66(19):9509-9518.
[10]Walser T C, Rifat S, Ma X, et al.Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer [J]. Cancer Res,2006,66:7701-7707.
[11]Pradelli E, Babou K S, Michiels J F, et al. Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs [J]. Int. J. Cancer,2009,125:2586-2594.
[12]Maekawa S, Iwasaki A, et al. Association between the expression of chemokin receptors CCR7 and CXCR3, and lymph node metastatic potential in lung adenocarcinoma [J]. Oncology Reports,2008,19:1461-1468.
[13]Monteagudo C, Martin J M, Jorda E, et al. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma:correlation with clinicopathologic prognostic factors [J].J Clin Pathol,2007,60:596-599.
[14]Kawada K, Hosogi H, et al. Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes [J]. Oncogene,2007,26:4679-4688.
[15]Zipin R A, Meshel T, et al. CXCL10 promotes invasion-related properties in human colorectal carcinoma cells [J]. Cancer Res,2007,67:3396-405.
[16]Scotten C J, Wilson J L, Scott K, et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer [J]. Cancer Res,2002,62:5930-5938.
[17]Shi M, Guo R P, Zhang C Q, et al. Expression of CXCR3 in Hepatocellular Carcinoma [J]. Chinese Journal of Cancer,2006,25(10):1232-1237.
[18]Smith M, Luker K E, Gargow J R, et al. CXCR4 regulates.growth of both primary and metastatic breast cancer [J]. Cancer Res,2004,64:04-12.
[19]《乳腺癌Her2检测指南(2009版)》编写组.乳腺癌Her2检测指南(2009版).中华病理学杂志,2009,38(12)：836-840.
[20]姚晓英,宋晖.趋化性细胞因子与乳腺癌的转移[J].中国癌症杂志,2003,13(4)：381-384.
[21]Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4 [J]. Semin Cancer Biol,2004,4(3):171-179.
[22]Furuya M, Suyama T, Usui H, et al. Up-regulation of CXC mokines and their receptors:implications for proinflammatory microronments of ovarian carcinomas and endometriosis [J]. Hum Pathol 2007,38 (11):1676-87.
[23]Luster AD, Leder P. IP-10, a C-X-C chemokine, elicits a potent thymus dependent antitumor response in vivo [J]. J Exp Med,1993,178:1057-65.
[24]Goldberg-Bittman L, Sagi-Assif 0, Meshel T, et al. Cellular character-istics of neuroblastoma cells:regulation by the ELR-CXC chemokine CXCL10 and expression of a CXCR3-like receptor [J]. Cytokine 2005,29:105-17.
[25]Suyama T, Furuya M, Nishiyama M, et al. Up-regulation of the interferon gamma (IFN-gamma)-inducible chemokines IFN-inducible T-cell alpha chemoattractant and monokine induced by IFN-gamma and of their receptor CXC receptor 3 in human renal cell carcinoma [J]. Cancer,2005,103(2): 258-267.
[26]Robledo M M, Bartolome R A, Longo N, et al. Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells [J]. J Biol Chem,2001,276(48):45098-45105.
[27]Kawada K, Sonoshita M, Sakashita H, et al. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes [J]. Cancer Res,2004, 64 (11):4010-4017.
[1]Balkwill F, Mantovani A. Inflammation and cancer:back to Virchow? [J].Lancet,2001,357(9255):539-545.
[2]姚晓英,宋晖.趋化性细胞因子与乳腺癌的转移[J].中国癌症杂志,2003,13(4)：381-384.
[3]Richmond A, Thomas H G. Melanoma growth stimulatory activity:isolation from human melanoma tumors and characterization of tissue distribution[J]. Cell Biochem,36(1988):185-198.
[4]Addison C L, Daniel T O, et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+CXC chemokine-induced angiogenic activity [J]. Immunol,165 (2000):5269-5277.
[5]Dhawan P, Richmond A.Role of CXCL1 in tumorigenesis of melanoma [J]. J Leukoc Biol,2002,72(1):9-18.
[6]Luan J, Shattuck B H,et al. Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression [J].J Leukoc Biol,1997,62:588-597.
[7]Burger M, Burger J A, et al. Point mutation causing constitutive signaling of CXCR2 leads to transforming activity similar to Kaposi's sarcoma herpesvirus-G protein-coupled receptor [J]. Immunol,1999,163:2017-2022.
[8]Gershengorn M C, Geras R E, et al. Chemokines activate Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor in mammalian cells in culture [J].J Clin Invest,1998,102:1469-1472.
[9]Park J Y, Park K H, et al. CXCL5 overexpression is associated with late stage gastric cancer [J]. Cancer Res Clin Oncol,2007,133:835-840.
[10]Miyazaki H, Patel V, Wang-H. Down-regulation of CXCL5 inhibits squamous carcinogenesis [J]. Cancer Res,2006,66:4279-4284.
[11]Arenberg D A, Keane M P, DiGiovine B, et al. Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer [J]. J Clin Invest,1998,102:465-472.
[12]Proost P, Wuyts A, et al. Human and bovine granulocyte. chemotactic protein-2:complete amino acid sequence and functional characterization as chemokines[J]. Biochemistry,1993,32:10170-10177.
[13]Strieter R M, Polverini P J, et al.The functional role of the ELR motif in CXC chemokine-mediated angiogenesis[J]. J Biol Chem,1995,270:27348-27357.
[14]E. Van Coillie, I. Van Aelst, A. Wuyts, R. Vercauteren, R. Devos, C. De Wolf-Peeters, J. Van Damme, G. Opdenakker. Tumor angiogenesis induced by granulocyte chemotactic protein-2 as a countercurrent principle [J]. Am J Pathol,2001,159:1405-1414.
[15]A. Li, M.L. Varney, J. Valasek, M. Godfrey, B. J. Dave, R. K. Singh. Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis [J]. Angiogenesis,2005,8:63-71.
[16]H. Kamohara, M. Takahashi, T. Ishiko, M. Ogawa, H. Baba. Induction of interleukin-8 (CXCL-8) by tumor necrosis factor-alpha and leukemia inhibitory factor in pancreatic carcinoma cells:Impact of CXCL-8 as an autocrine growth factor [J]. Int J Oncol,2007,31:627-632.
[17]M. L. Varney, S. L. Johansson, R. K. Singh.Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma [J]. Am J Clin Pathol,2006,125:209-216.
[18]S. Molica, G. Vitelli, D. Levato, L. Levato, A. Dattilo, G.M. Gandolfo, Clinico-biological implications of increased serum levels of interleukin-8 in B-cell chronic lymphocytic leukemia [J]. Haematologica,1999,84:208-211.
[19]A. E. Proudfoot, T. M. Handel, Z. Johnson, E. K. Lau, P. LiWang, I. Clark-Lewis, F. Borlat, T. N. Wells, M.H.Kosco-Vilbois. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines [J]. Proc Natl Acad Sci USA,2003,100:1885-1890.
[20]De Larco JE, Wuertz BR, Rosner KA, et al. A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells [J].Am J Pathol,2001,158(2):639-646.
[21]Freund A,Chauveau C,Brouillet JP, et al. IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells[J].Oncogene,2003,22(2):256-265.
[22]A. Wuyts, N. Van Osselaer, A. Haelens, I. Samson, P. Herdewijn, A. Ben-Baruch, J.J. Oppenheim, P. Proost,J. Van Damme. Characterization of synthetic human granulocyte chemotactic protein 2:usage of chemokine receptors CXCR1 and CXCR2 and in vivo inflammatory properties [J]. Biochemistry,1997,36:2716-2723.
[23]M.N. Wente, M. P. Keane, M. D. Burdick, H. Friess, M. W.Buchler, G.0. Ceyhan, H. A. Reber, R. M. Strieter,O. J. Hines. Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis [J]. Cancer Lett,2006,241:221-227.
[24]Y.M. Zhu, S. J. Webster, D. Flower, P. J. Woll. Interleukin-8/CXCL8 is a growth factor for human lung cancer cells [J].Br J Cancer,2004,91:1970-1976.
[25]Zhuo Tang, M. D. Minghuan Yu, M. D. Ph. D. Fred Miller, Ph. D. Richard S. Berk, Ph. D. Gerard Tromp, Ph. D. Mary Ann Kosir, M. D. Increased invasion through basement membrane by CXCL7-transfected breast cells [J]. The American Journal of Surgery (2008) 196,690-696.
[26]Takahito Suyama, Mitsuko Furuya, Mariko Nishiyama, et al. Up-Regulation of the Interferon γ (IFN-I)-Inducible Chemokines IFN-Induciblea T-Cell Chemoattractant and Monokine Induced by IFN-I and of their Receptor CXC Receptor 3 in Human Renal Cell Carcinoma [J]. Cancer 2005;103:258-67.
[27]陈瑜,张德新,郭长存,等.趋化因子受体CXCR3在胃癌中的表达[J].胃肠病学,2004;9(5)：266-69.
[28]Lilach Goldberg-Bittman, Eran Neumark,Orit Sagi-Assif,et al. The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines [J]. Immunology Letters 2004;92:171-178.
[29]Dipak Datta,.Jesse A. Flaxenburg, Sreenivas Laxmanan, et.al. Ras-induced Modulation of CXCL10 and Its Receptor Splice Variant CXCR3-B in MDA-MB-435 and MCF-7 Cells:Relevance for the Development of Human Breast Cancer [J]. Cancer Res 2006; 66(19):9509-18.
[30]T. C. Walser, S. Rifat, X. Ma, N. Kundu, C. Ward,0. Goloubeva, M. G. Johnson, J. C. Medina, T. L. Collins, A.M. Fulton. Antagonism of CXCR3 inhibits lung metas-tasis in a murine model of metastatic breast cancer [J]. Cancer Res,2006,66:7701-7707.
[31]Emmanuelle Pradelli, Babou Karimdjee S, Jean F M, et al. Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs [J]. Int J Cancer,2009,125:2586-2594.
[32]Shinichi Maekawa,Akinori Iwasaki, Takayuki Shirakusa, et,al. Association between the expression of chemokin receptors CCR7 and CXCR3, and lymph node metastatic potential in lung adenocarcinoma [J]. Oncology Reports,2008,19:1461-1468.
[33]Monteagudo C, Martin JM, Jorda E, Llombart-Bosch A. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathologic prognostic factors[J]. J Clin Pathol,2007,60:596-9.
[34]Kawada K, Hosogi H, Sonoshita M, et al. Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes[J]. Oncogene,2007,26:4679-88.
[35]Zipin-Roitman A, Meshel T, Sagi-Assif 0, et al. CXCL10 promotes invasion-related properties in human colorectal carcinoma cells[J]. Cancer Res,2007,67:3396-405.
[36]Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis[J]. Nature,2001,410:50-56.
[37]Li F,Zhu HS, Han ZQ,et al. Effects of chemokine receptor and its ligand on migration of ovarian cancer cells [J]. cancer,2005,24(1):23-27.
[38]Lee BC,Lee TH, Avraham S, et al. Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1 alpha in breast cancer cell migration through human brain microvascular endothelial cells [J].Mol Cancer Res,2004,2(6):327-338.
[39]Schimanski CC, Schwald S, Simiantonaki N, et al.Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer [J]. Clin Cancer Res,2005,11(5):1743-1750.
[40]Eisenhardt A,Frey U,Tack M,et al.Expression analysis and potential functional role of the CXCR4 chemokine receptor in bladder cancer [J]. Eur Urol,2005,47(1):111-117.
[41]Mochizuki H, Matsubara A, Teishima J, et al. Interaction of Ligand receptor system between stromal-cell-derived factor-1 and CXC chemokine receptor 4 in human prostate cancer:a possible predictor of metastasis [J]. Biochem Biophys Res Commun,2004,320(3):656-663.
[42]Sato N, Matsubayashi H, Fukushima N, et al. The chemokine receptor CXCR4 is regulated by DNA methylation in pancreatic cancer [J]. Cancer Biol Ther,2005,4(1):70-76.
[43]Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4 [J]. Semin Cancer Biol,2004,4(3):171-179.
[1]魏永昆,朱虹光,周平,等.滑膜肉瘤32例临床病理分析.诊断病理学杂志,2002,9(2)：73-76.
[2]杨翎,范钦和,张炜明.滑膜肉瘤融合基因SYT2SSX的检测及意义分析.临床与实验病理学杂志,2004,20(5)：576-9.
[3]Tatsuya Hosono, Mitsugu Hironaka, Akira Kobayashi, et, al. Primary Pulmonary Synovial Sarcoma Confirmed by Molecular Detection of SYT-SSX1 Fusion Gene Transcripts:a Case Report and Review of the Literature. J Clin Oncol,2005,35(5)274-279.
[4]Smith TA, Machen SK, Fisher C, et, al. Usefulness of cytokeratin subsets for distinguishing monophasic synovial sarcoma from malignant peripheral nerve sheath tumor. Am J Clin Pathol,1999,112(5):641-8.
[5]Mai P. Hoang, Prasanna Sinkre, Jorge Albores-Saavedra, et, al. Expression of Protein Gene Product 9.5 in Epithelioid and Conventional Malignant Peripheral Nerve Sheath Tumors. Arch Pathol Lab Med,2001,125:1321-1325.
[6]Hiroshi Katol, Masahito Hatori, Shoichi Kokubun, et, al. CA125 Expression in Epithelioid Sarcoma. J Clin Oncol 2004,34(3)149-154.
[7]Mousa A. Al-Abbadi,; Nidal M. Almasri, Samer Al-Quran, et, al. Cytokeratin and Epithelial Membrane Antigen Expression in Angiosarcomas. Arch Pathol Lab Med,2007,131:288-292.
[8]Kimberly H Allison, Brian J. Yoder, Mary P. Bronner, et, al. Angiosarcoma Involving the Gastrointestinal Trac A Series of Primary and Metastatic Cases. Am J Surg Pathol,2004,28:298-307.
[9]Boudovd L, Michal M, Kinkor Z, et, al. sclerosing epitheral f ibrosarcoma. Cesk Patol,2001,37(4):158-62.
[10]Jun Lwata, Christopher D. M. Fletcher. immunohistochemical detection of CK and EMA in leiomyosarcoma, pathology international,2000, 50:7-14
[11]Kokada, T Hasegawa, R Yokoyama, et, al. Osteosarcoma with cytokeratin expression:a clinicopathological study of six cases with an emphasis on differential diagnosis from metastatic cancer. J Clin Pathol,2003, 56:742-746.
[12]Okada K, Hasegawa T, Yokoyama R. Rossete-forming epithelioid osteosarcoma:a histologic subtype with highly aggressive clinical behavior. Hum Pathol,2001 Jul,32(7):726-33.
[13]Louis Guillou, Jean Benhattar, Carole Gengler, et, al. Translocation positive Low-grade Fibromyxoid Sarcoma:Clinicopathologic and Molecular Analysis of a Series Expanding the Morphologic Spectrum and Suggesting Potential Relationship to Sclerosing Epithelioid Fibrosarcoma. Am J Surg Pathol 2007,31:1387-1402.
[14]王坚,朱雄增.纤维肉瘤少见亚型的诊断及鉴别诊断.Chin J Pathol,32(5)：469-74.
[15]Collini, Pabla, Sampietro, Giuseppe, Bertulli, Rossella. Cytokeratin Immunoreactivity in 41 Cases of ES/PNET Confirmed by Molecular Diagnostic Studies. Am J Surg Pathol 2001,25(2):273-4.
[16]W Glenn McCluggage, Vaiyapuri P Sumathi, Marisa R Nucci, et, al. Ewing family of tumours involving the vulva and vagina:report of a series of four cases. J Clin Pathol,2007,60:674-680.
[17]Srivastava A, Rosenberg AE, Selig M, et, al. Keratin-positive Ewing's sarcoma:an ultrastructural study of 12 cases. Int J Surg Pathol,2005, 13(1):43-50.
[18]Andrew L. Folpe, MD, John R. Goldblum, MD, Brian P. Rubin, MD, et, al. Morphologic and Immunophenotypic Diversity in Ewing Family Tumors. Am J Surg Pathol 2005,29:1025-1033.
[19]魏清柱,刘艳辉,庄恒国,等.RT-PCR法检测EWS-FLI融合基因诊断尤文肉瘤与外周原始神经外胚层瘤.J Diag Pathol, February 2007,14(1):32-35。
[20]Sandra Gebhard, M.D., Jean-Michel Coindre, M. D, et, al. Pleomorphic Liposarcoma:Clinicopathologic, Immunohistochemical and Follow-up Analysis of 63 Cases. Am J Surg Pathol,25(6):601-616.
[21]Masanori Hisaoka, Tsuyoshi Ishida, Tseng-Tong Kuo, et, al. Clear Cell Sarcoma of Soft Tissue A Clinicopathologic, Immunohistochemical and Molecular Analysis of 33 Cases. Am J Surg Pathol,2008,32:452-460.
[22]Mi-Woo Lee, Kowan-Ja Jee, Jae-Yoon Ro, et, al. Proximal-type epithelioid sarcoma:case report and result of comparative genomic hybridization. J Cutan Pathol,2004,31:67-71.